Prediction Market Signals Potential US Government Stakes in IonQ Micron and Anduril RBI Dividend and Geopolitical Tensions Set the Stage for Indian Markets This Week Endurance Technologies IPO Opens Key Details and Market Implications Shipping Tycoon Teo Siong Seng Faces Container PriceFixing Allegations Implications for Global Trade Birkenstock BIRK Surges 33 Following 250 Million Share Buyback Announcement FIS Secures Major Client Wins Signaling Potential Turnaround Momentum AKBA Q1 2026 Earnings EPS Misses Estimates as Stock Holds Steady TBN Q1 2026 Earnings EPS Miss Reflects Exploration Costs and No Revenue Generation BILL Holdings Q1 2026 Earnings EPS Smashes Estimates as Platform Gains Traction PLX Q1 2026 Earnings Major EPS Beat Driven by Strong Operational Performance VerifyMe Inc VRME Q4 2025 Earnings EPS Misses Estimates Amid Challenging Quarter Vertex Inc VERX Q1 2026 Earnings EPS Beat Drives Modest Share Gains Revenue Unreported Inogen INGN Sees Mild Uptick Consolidates Near Key Resistance Calamos Convertible Opportunities and Income Fund CHI Edges Higher Navigating Support and Resistance New Concept Energy Inc GBR Declines 2 Amidst Light Trading Eyes Key Support at 069 Wynn Resorts WYNN Surges 34 as Bulls Test Key Resistance at 10628 GJT Shows Modest Gains Near Support as Volatility Remains Low Stellantis Turnaround Plan Prediction Market Regulation Oura IPO Filing Lead CNBC Morning Squawk GBLI Q1 2026 Earnings EPS Falls Short of Estimates as Underwriting Results Weigh Flutter Entertainment FLUT Holds Steady Near Support Following Modest Uptick GDL Fund Holding Steady Slight Uptick Signals Cautious Optimism Nexstar Media Group NXST Edges Lower Amid Cautious Trading Support and Resistance Levels in Focus Cenovus Energy CVE Holds Near Resistance as Crude Uncertainties Linger AleAnna Inc ANNA Rallies 63 as Bulls Approach Resistance at 337 Mayville Engineering MEC Gains Ground Support Holds Firm at 2577 Indigo Acquisition Corp Unit INACU Holds Steady Near 1028 as SPAC Market Digests Recent Catalysts Generate Biomedicines GENB Faces Selling Pressure as Shares Slide Over 8 Key Levels in Focus